Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in a phase III trial evaluating Zuprata, its suspension formulation of triamcinolone acetonide, in combination with Eylea for the treatment of macular edema associated with retinal vein occlusion.
The trial is slated to enroll 460 patients with retinal vein occulsion to assess the efficacy and safety of the combination therapy. In 1 arm of the study, patients will receive the combination therapy at the beginning of the trial, intravitreal Eylea at week 4 and the combination therapy again at weeks 12 and 24. Patients in the control arm will receive intravitreal Eylea alone every 4 weeks until week 24.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside enrolls first patient in phase III trial of Zuprata combination therapy appeared first on MassDevice.